RSS-Feed abonnieren
DOI: 10.1055/s-0029-1243203
© Georg Thieme Verlag KG Stuttgart · New York
Laparoscopic Unilateral Adrenalectomy in Children for Isolated Primary Pigmented Nodular Adrenocortical Disease (PPNAD): Case Report and Literature Review
Publikationsverlauf
Publikationsdatum:
22. Januar 2010 (online)
![](https://www.thieme-connect.de/media/ejps/201004/lookinside/thumbnails/10.1055-s-0029-1243203-1.jpg)
Introduction
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism, characterized by small or normal-sized adrenal glands containing multiple cortical nodules; it is a rare syndrome and its main endocrine manifestation is adrenocorticotropic hormone-independent Cushing's syndrome. ACTH-independent adrenocortical causes of Cushing's syndrome account for up to 15% of all cases of Cushing's syndrome in children older than 7 years.
In younger children, ACTH-independent Cushing's syndrome may account for as many as half of all Cushing's syndrome cases, mostly due to adrenal tumors [1]. PPNAD may occur in an isolated form or in association with a multiple neoplasia syndrome, the Carney complex (32% of cases of PPNAD to 90% of cases, in some series).
This syndrome consists of a complex of spotty skin pigmentation (lentigines), myxomas (cardiac, cutaneous), mammary myxoid lesions, testicular tumors, pituitary adenomas, psammomatous melanotic schwannomas, and possibly other neoplasms, including adrenocortical and thyroid follicular carcinomas, testicular tumors and ovarian cysts, plus endocrine overactivity [2].
Isolated PPNAD is the result of genetic processes associated with defects of the cAMP signaling pathway. The patient is a carrier of a known inactivating mutation of the protein kinase A type R1A regulatory subunit (PRKAR1A) gene. Isolated PPNAD tissue expresses consistently high levels of phosphodiesterase 11A (PDE11A); this finding has led to the identification of PDE11A mutations as a low-penetrance predisposing factor to PPNAD. Both PRKAR1A and PDE11A gene products control the cAMP signaling pathway, which can be altered at various levels in endocrine tumors. Screening of family members is mandatory in this group of patients [3].
Primary pigmented nodular adrenocortical tumors are characterized by lipofuscin-containing, autonomously functioning, cortisol-producing nodules surrounded by mostly atrophic adrenocortical and normal adrenomedullary tissue; usually both glands are affected. Microscopically, the nodules consist of large cortical cells with eosinophilic cytoplasm and large hyperchromatic nuclei with prominent nucleoli; the cytoplasm is rich in lipofuscin pigment and, possibly, neuromelanin.
Clinically, signs of Cushing's syndrome develop in these patients: the skin is fragile and thin; purplish pink stretch marks are noted on the abdomen, thighs, buttocks, arms, and breasts; upper-body obesity, a round face, increased fat around the neck, and thin arms and legs are observed; children tend to be obese, with slowed growth rates and pubertal delay; women usually have excessive hair growth on their face, neck, chest, abdomen, and thighs.
Clinically evident Cushing's syndrome exists in 84% of patients with PPNAD, while 6% of patients with PPNAD have only biochemical evidence of adrenocortical hyperfunction, and 10% of patients may remain undiagnosed due to the paucity of symptoms.
The biochemical and radiological evaluation of patients with Cushing's syndrome caused by PPNAD reveals the ACTH-independent nature of this disorder; plasma levels of ACTH are low, normal or undetectable; adrenal steroid production is not suppressible by high-dose dexamethasone. Moreover, most patients have a paradoxical increase in UFC excretion after the administration of high-dose dexamethasone.
Computerized tomography (CT) examination of the abdomen shows adrenal glands of normal size in half of the cases. The presence of multiple small adrenal nodules with intervening segments of atrophic adrenal cortex gives a “string of beads” appearance that is characteristic of PPNAD, especially in the 12–18 years age group.
Beyond the age of 18 years, unilateral 2–3 cm adrenal macronodules are common in PPNAD, making it impossible to distinguish Cushing's syndrome due to PPNAD from the much more common ACTH-independent adrenal adenomatous hyperplasia based on radiological criteria only.
In recent years, laparoscopic bilateral adrenalectomy followed by hormone substitution has become the standard therapy for these adrenal lesions in adult patients. A few reports in the literature have also described unilateral adrenalectomy as an effective cure for primary hypercortisolism due to PPNAD.
We report the case of a young girl successfully treated at our institution by laparoscopic unilateral adrenalectomy for an isolated PPNAD.
References
- 1 Stratakis CA. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropinindipendent cushing syndrome). Endocr Dev. 2008; 13 117-132
- 2 Horvath A, Stratakis C. primary pigmented nodular adrenocortical disease and Cushing's syndrome. Arq Bras Endocrinol Metabol. 2007; 51 ((8)) 1238-1244
- 3 Cazabat L, Ragazzon B, Groussin L. et al . PRKAR1A mutations in primary pigmented nodular adrenocortical disease. Pituitary. 2006; 9 ((3)) 211-219
- 4 Horvath A, Giatzakis C, Robinson-White A. et al . Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res. 2006; 66 ((24)) 11571-11575
- 5 Grant CS, Carney JA, Carpenter PC. et al . Primary pigmented nodular adrenocortical disease: diagnosis and management. Surgery. 1986; 100 ((6)) 1178-1184
- 6 Larsen JL, Cathey WJ, Odell WD. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome. Case report and review of the literature. Am J Med. 1986; 80 ((5)) 976-984
- 7 Anding K, Köhler G, Böhm N. et al . Primary pigmented nodular adrenocortical dysplasia. A rare cause of Cushing's syndrome. Dtsch Med Wochenschr. 1996; 121 ((43)) 1321-1324
- 8 Sarlis NJ, Chrousos GP, Doppman JL. et al . Primary pigmented nodular adrenocortical disease: reevaluation of a patient with Carney complex 27 years after unilateral adrenalectomy. J Clin Endocrinol Metab. 1997; 82 ((4)) 1274-1278
- 9 Imai T, Funahashi H, Tanaka Y. et al . Adrenalectomy for treatment of Cushing syndrome: results in 122 patients and long-term follow-up studies. World J Surg. 1996; 20 ((7)) 781-786 discussion 786-787
- 10 Zhu Y, Wu YX, Rui WB. et al . Primary pigmented nodular adrenocortical disease – report of 5 cases. Zhonghua Wai Ke Za Zhi. 2005; 43 ((14)) 944-947
- 11 Cohen O, Bogat S, Dolitzki M. et al . Successful pregnancy after unilateral adrenalectomy in a case of primary pigmented adrenocortical disease. J Matern Fetal Neonatal Med. 2005; 17 ((2)) 161-163
- 12 Bocca G, van Mil EG, Voorhoeve PG. et al . A girl with Cushing's syndrome due to primary pigmented nodular adrenocortical disease. Ned Tijdschr Geneeskd. 2006; 150 ((43)) 2390-2393
Correspondence
Dr. R. Guanà
Regina Margherita Children's Hospital
Division of Pediatric Surgery
Piazza Polonia 94
10100 Turin
Italy
Telefon: +39 0338 770 47 16
Fax: + 39 0113 13 54 86
eMail: riccardoguan@gmail.com